Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 in Head and Neck Cancer
NCT06819228Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of panitumumab in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Maximum tumor concentrating dose up to 21 days. Started Apr 2025; status: recruiting.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06819228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819228.